{
    "symbol": "BIOC",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-28 18:26:06",
    "content": " Cost of revenues for the third quarter of 2022 was $5.8 million, compared with $11.3 million a year ago, with the decrease primarily related to lower COVID-19 testing volume. G&A expenses for the third quarter of 2022 were $3 million, compared with $3.5 million for the third quarter of 2021, with the decrease primarily due to lower stock-based compensation and lower headcount. Sales and marketing expenses for this year's third quarter were $1 million compared with $1.9 million a year ago, with the decrease due primarily to reduction in sales commissions expense. Operating expenses for the first nine months of 2022 were $49.5 million and included cost of revenues of $24.1 million, R&D expenses of $4.9 million, G&A expenses of $4.2 million and sales and marketing expenses of $6.3 million, with G&A $3.5 million of expenses were nonrecurring."
}